IL308058A - Molephantin derivatives useful in the treatment of cancer - Google Patents
Molephantin derivatives useful in the treatment of cancerInfo
- Publication number
- IL308058A IL308058A IL308058A IL30805823A IL308058A IL 308058 A IL308058 A IL 308058A IL 308058 A IL308058 A IL 308058A IL 30805823 A IL30805823 A IL 30805823A IL 308058 A IL308058 A IL 308058A
- Authority
- IL
- Israel
- Prior art keywords
- molfentin
- history
- cancer
- useful
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10202104429U | 2021-04-29 | ||
| PCT/SG2022/050251 WO2022231520A1 (en) | 2021-04-29 | 2022-04-27 | Molephantin derivatives useful in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308058A true IL308058A (en) | 2023-12-01 |
Family
ID=83848883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308058A IL308058A (en) | 2021-04-29 | 2022-04-27 | Molephantin derivatives useful in the treatment of cancer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250304544A1 (https=) |
| EP (1) | EP4330241A4 (https=) |
| JP (1) | JP2024517443A (https=) |
| CN (1) | CN117377663A (https=) |
| AU (1) | AU2022265461A1 (https=) |
| IL (1) | IL308058A (https=) |
| WO (1) | WO2022231520A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115919833A (zh) * | 2023-01-31 | 2023-04-07 | 暨南大学附属第一医院（广州华侨医院） | 一种CutC蛋白抑制剂及其应用 |
| AU2024337402A1 (en) * | 2023-09-06 | 2026-03-26 | Nanyang Biologics Pte. Ltd. | Collective synthesis of phantomolin family through total synthesis of the sesquiterpene lactone molephantin |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3418724B2 (ja) * | 2000-02-10 | 2003-06-23 | 国立医薬品食品衛生研究所長 | セスキテルペノイド化合物及びそれを含む医薬 |
| JP2005002050A (ja) * | 2003-06-12 | 2005-01-06 | Shiseido Co Ltd | 美白剤及びこれを配合した皮膚外用剤 |
| CN102000072A (zh) * | 2009-09-01 | 2011-04-06 | 奇复康药物研发(苏州)有限公司 | 偶联有一氧化氮供体的抗肿瘤天然药物及其医药用途 |
| CN103732586B (zh) * | 2011-04-07 | 2016-02-03 | 南洋理工大学 | 作为抗癌剂的乙酰基丹参酮iia(ata) |
| WO2019040335A1 (en) * | 2017-08-19 | 2019-02-28 | University Of Rochester | MICHELOLID DERIVATIVES, PREPARATION METHODS AND THEIR USE AS ANTICANCER AND ANTI-INFLAMMATORY AGENTS |
| CN111153910B (zh) * | 2020-01-09 | 2021-07-30 | 沈阳药科大学 | 地胆草种内酯衍生物及其制备方法和用途 |
-
2022
- 2022-04-27 JP JP2023566885A patent/JP2024517443A/ja active Pending
- 2022-04-27 WO PCT/SG2022/050251 patent/WO2022231520A1/en not_active Ceased
- 2022-04-27 EP EP22796282.6A patent/EP4330241A4/en active Pending
- 2022-04-27 AU AU2022265461A patent/AU2022265461A1/en active Pending
- 2022-04-27 US US18/556,616 patent/US20250304544A1/en active Pending
- 2022-04-27 IL IL308058A patent/IL308058A/en unknown
- 2022-04-27 CN CN202280031592.6A patent/CN117377663A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022265461A1 (en) | 2023-11-16 |
| JP2024517443A (ja) | 2024-04-22 |
| US20250304544A1 (en) | 2025-10-02 |
| EP4330241A4 (en) | 2025-03-19 |
| EP4330241A1 (en) | 2024-03-06 |
| WO2022231520A1 (en) | 2022-11-03 |
| CN117377663A (zh) | 2024-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL260400B (en) | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies | |
| IL309086A (en) | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers | |
| IL270511A (en) | Combination therapies using niraparib and pembrolizumab for treating cancer | |
| IL286079A (en) | Imidazolonylquinoline compounds and therapeutic uses thereof | |
| IL291183A (en) | Tools and methods for vaginal access | |
| JP1789738S (ja) | 皮膚治療機器 | |
| PL3429571T3 (pl) | Kombinacje inhibitorów lsd1 do zastosowania w leczeniu chorób nowotworowych | |
| IL287904A (en) | Combination treatment of arthritic disease | |
| EP3471717A4 (en) | TREATMENT OF PLATE CELL CARCINOMAS WITH ERK INHIBITORS | |
| EP4199869A4 (en) | ULTRASOUND TREATMENT OF VITREOUS OPACITIES | |
| EP4149453A4 (en) | Combination treatment of liver disorders | |
| EP4493175A4 (en) | MIRDAMETINIB TREATMENT | |
| EP4003299A4 (en) | Treatment of skin disorders with topical tapinarof-egfr inhibitor compositions | |
| EP3735209A4 (en) | TREATMENT OF THE PROGRESSION OF MYOPOIA | |
| IL308058A (en) | Molephantin derivatives useful in the treatment of cancer | |
| IL283899A (en) | Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer | |
| EP4393493A4 (en) | PARP INHIBITOR-RESISTANT PATIENT TREATED WITH TH-302 | |
| IL280343A (en) | Treatment of mucopolysaccharidosis iva | |
| IL282273A (en) | Urea derivatives for treating and/or preventing cancer | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| IL280395A (en) | Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers | |
| IL291424A (en) | Use of dkk-1 inhibitors for treating cancer | |
| EP4401721A4 (en) | CANCER TREATMENT | |
| KR20240099184A9 (ko) | 재생불량성 질환 치료를 위한 mrna 레귤론 요법 | |
| EP4291301C0 (en) | NON-INVASIVE CANCER TREATMENT |